Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$3365.00
-85.00 (-2.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $5.1B · quality 34.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$119.3B
P/E
15.5x
↓EV/EBITDA
6.7x
↓ROE
4.3%
↑Gross Margin
51.1%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.5%
FCF CAGR
+18.1%
FCF margin
6.8%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $105.16B · net income $5.68B · FCF $7.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $105.16B | $105.16B | $102.89B | $103.26B | $110.18B |
| Net Income | $5.68B | $5.68B | $4.55B | $6.65B | $10.57B |
| EBITDA | $10.99B | $10.99B | $8.97B | $11.72B | $17.28B |
| EPS | 160.36 | 160.36 | 126.80 | 178.93 | 277.39 |
| Gross Margin | 51.1% | 51.1% | 50.6% | 53.4% | 54.1% |
| Operating Margin | 7.7% | 7.7% | 5.6% | 8.2% | 13.1% |
| Net Margin | 5.4% | 5.4% | 4.4% | 6.4% | 9.6% |
| Balance Sheet | |||||
| Current Ratio | 4.29 | 4.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.19B | $7.19B | $-9.78B | $5.13B | $4.36B |
| Returns | |||||
| ROE | 4.3% | 4.3% | 3.6% | 5.2% | 8.2% |
| Valuation | |||||
| P/E | 15.48 | 15.48 | 24.72 | 18.28 | 13.28 |
| EV/EBITDA | 6.74 | 6.74 | 8.82 | 6.36 | 5.32 |
| P/B | 0.91 | 0.91 | 0.88 | 0.96 | 1.09 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | -0.4% | -6.3% | — |
| EPS Growth | 26.5% | 26.5% | -29.1% | -35.5% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
23.0%
EPS terminal req.
$298.59
Spread vs growth
3.4%
5Y implied EPS CAGR
17.6%
EPS terminal req.
$361.29
Spread vs growth
8.8%
10Y implied EPS CAGR
13.8%
EPS terminal req.
$581.86
Spread vs growth
12.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.1%
Start / end P/E
23.2x → 21.0x
EPS bridge
126.80 → 160.36
Residual
-2.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.